DASAPHARM LIMITEDActive
Key figures
Amounts are in USD (the currency of the accounts).
Like most small UK companies, DASAPHARM LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.
Ratios
2024Balance sheet structure
Filed accounts2020–2024
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Cash at bank and in hand | — | 300,998 | 667,777 | 871,546 | 2,079,544 |
| Total assets | 381,443 | 731,509 | 1,575,639 | 2,355,547 | 4,776,962 |
| Total liabilities | 471,999 | 892,085 | 1,725,164 | 2,487,687 | 4,896,923 |
| Net assets / total equity | -94,818 | -160,576 | -149,525 | -132,140 | -119,961 |
| Average number of employees | 0 | 0 | 0 | 0 | 0 |
A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.
Principal activity
Accounts 2024The principal activity of the company during the year under review was wholesale pharmaceutical goods.
As described in the company's latest filed accounts.
Summary: DASAPHARM LIMITED
Company
DASAPHARM LIMITED is a private limited company registered with Companies House under company number 09325869. It was incorporated on 25 Nov 2014. Its status is active. The registered office is in London (NW3). Its nature of business (SIC 2007) is wholesale of pharmaceutical goods (46460).
Accounts
The latest accounts in the database are for 2024 (period ending 31 Dec 2024); the company files small company accounts (filleted). Net assets were −119,961 USD, up 9.2% on the previous year. Cash at bank and in hand was 2,079,544 USD. Total assets were 4,776,962 USD and total liabilities 4,896,923 USD. The company had an average of 0 employees. Figures are available for 5 financial years (2020–2024).
Control and charges
3 persons with significant control are registered.
Filing deadlines
The next accounts are due by 31 Dec 2026. The next confirmation statement is due by 6 Apr 2027.